Tel Aviv, Israel / Vancouver, Canada, April 06, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the closing of its United States only public offering made on a reasonable best efforts…

Source

Previous articleExpanding Your Horizons: The Ultimate Guide to Attending a Psychedelic Conference
Next articlePsychedelics Weekly – Roland Griffiths Faces the End, The NBA Lifts Its Cannabis Ban, and The Rising Popularity of Mushrooms for Moms